

This communication should be viewed by:

Primary Care Providers
Behavioral Health Providers
Clinical staff
Specialist
Claims and Billing Department
Facility/Practice staff

Pharmacy Policy Updates

MVP Health Care® (MVP) appreciates your continued partnership in supporting our Members.

As part of our ongoing policy review process, MVP reviews all Medical Policies at least annually and communicates changes that may impact Providers. To view current MVP Medical Policies, *Sign In* at **mvphealthcare.com** and select *Resources*, then *Medical Policies*. The policies included in this communication are identified by the following status categories:

- **New** – Denotes a new policy
- **Updated** – Updated policies have content changes that may affect coverage criteria for services and/or drugs
- **Reviewed/No Changes** – Policies that have been reviewed but have no content change
- **Archived** – Denotes a policy that is no longer active

The following policies have upcoming effective dates as noted below. Policies effective June 1, 2026, and August 1, 2026, will be available for viewing. Hard copies are available upon request.

Pharmaceutical Policy Name	Status
<i>Effective June 1, 2026</i>	
Agents for Female Sexual Dysfunction	Updated
Gastric Acid Related Disorder Agents (formerly Proton Pump Inhibitors)	Updated
Preventive Services Medications	Updated
Select Immunomodulating Agents (formerly Select Injectables for Asthma)	Updated
Select Immunomodulating Agents Part B (formerly Select Injectables for Asthma Part B)	Updated
Spinal Muscular Atrophy	Updated
Weight Loss Medications	Updated
Zopapogene Imadenovex (Papzimeo) Medicare Part B	New Policy
Zopapogene Imadenovex (Papzimeos)	New Policy
<i>Effective August 1, 2026</i>	
Compounded (extemporaneous) Medications	Updated
Drug Utilization Review and Monitoring Program	Reviewed/No Changes
Gaucher Disease Treatment	Updated
Medicare Part B vs Part D Determination	Updated